SCHEMBL2291909

SCHEMBL2291909

Cc1nc(-c2cccc(I)c2)no1

nearest known ligand 0.77

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 2/20 0.77
CHRNA7 P36544 1/20 0.45
RAB9A P51151 7/20 0.44
NPC1 O15118 6/20 0.44
TP53 P04637 5/20 0.44
SMN1; SMN2 Q16637 4/20 0.44
MAPT P10636 3/20 0.44
POLB P06746 2/20 0.44
CA12 O43570 1/20 0.44
CA1 P00915 1/20 0.44
CA2 P00918 1/20 0.44
CA9 Q16790 1/20 0.44
CASP3 P42574 1/20 0.43
SENP7 Q9BQF6 1/20 0.43
PLK1 P53350 1/20 0.43
TRPM8 Q7Z2W7 1/20 0.43
TSHR P16473 1/20 0.42
MAPK1 P28482 1/20 0.42
TDP1 Q9NUW8 1/20 0.42
MEN1 O00255 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13130238 0.87 L3MBTL1 (1.00) L3MBTL1CHRNA7RAB9ANPC1TP53
SCHEMBL2090313 0.82 L3MBTL1 (0.82) L3MBTL1RAB9ANPC1TP53SMN1; SMN2
SCHEMBL13167415 0.81 L3MBTL1 (0.86) L3MBTL1RAB9ANPC1TP53SMN1; SMN2
SCHEMBL2618505 0.81 L3MBTL1 (0.86) L3MBTL1RAB9ANPC1TP53SMN1; SMN2
SCHEMBL16579414 0.81 L3MBTL1 (0.86) L3MBTL1RAB9ANPC1TP53SMN1; SMN2
SCHEMBL29176883 0.80 HTT (0.50) L3MBTL1RAB9ANPC1TP53SMN1; SMN2
SCHEMBL30817783 0.80 HTT (0.50) L3MBTL1RAB9ANPC1TP53SMN1; SMN2
SCHEMBL1353440 0.79 L3MBTL1 (0.77) L3MBTL1CHRNA7RAB9ANPC1TP53
SCHEMBL14363634 0.79 L3MBTL1 (0.77) L3MBTL1RAB9ANPC1TP53SMN1; SMN2
SCHEMBL10192395 0.79 L3MBTL1 (0.83) L3MBTL1RAB9ANPC1TP53SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117720535-B Pyrido [1, 2-a ] pyrimidine mesoionic derivative containing 1,2, 4-oxadiazole structure, and preparation and application thereof 贵州大学 2025-05-13 CN disclosed
CN-117720535-A Pyrido [1,2-a ] pyrimidine mesoionic derivative containing 1,2, 4-oxadiazole structure, and preparation and application thereof 贵州大学 2024-03-19 CN disclosed
US-20130172352-A1 5-MEMBERED HETEROCYCLE-BASED P38 KINASE INHIBITORS NOVARTIS AG (CH) 2013-07-04 US disclosed
US-20130172352-A1 5-MEMBERED HETEROCYCLE-BASED P38 KINASE INHIBITORS NOVARTIS AG (CH) 2013-07-04 US disclosed
US-8410160-B2 5-membered heterocycle-based P38 kinase inhibitors NOVARTIS AG (CH) 2013-04-02 US disclosed
US-8410160-B2 5-membered heterocycle-based P38 kinase inhibitors NOVARTIS AG (CH) 2013-04-02 US disclosed
US-20120264801-A1 5-MEMBERED HETEROCYCLE-BASED P38 KINASE INHIBITORS NOVARTIS AG (CH) 2012-10-18 US disclosed
US-20120264801-A1 5-MEMBERED HETEROCYCLE-BASED P38 KINASE INHIBITORS NOVARTIS AG (CH) 2012-10-18 US disclosed
US-8242117-B2 5-membered heterocycle-based p38 kinase inhibitors NOVARTIS AG (CH) 2012-08-14 US disclosed
US-8242117-B2 5-membered heterocycle-based p38 kinase inhibitors NOVARTIS AG (CH) 2012-08-14 US disclosed
EP-0828493-A4 4.4-(DISUBSTITUTED)CYCLOHEXAN-1-OLS-MONOMERS AND RELATED COMPOUNDS SMITHKLINE BEECHAM CORP (US) 1998-09-02 EP disclosed
EP-0799183-A4 3,3-(DISUBSTITUTED)CYCLOHEXAN-1-ONE MONOMERS AND RELATED COMPOUNDS SMITHKLINE BEECHAM CORP (US) 1998-03-25 EP disclosed
EP-0828493-A1 4.4-(DISUBSTITUTED)CYCLOHEXAN-1-OLS-MONOMERS AND RELATED COMPOUNDS SMITHKLINE BEECHAM CORPORATION (US) 1998-03-18 EP disclosed
EP-0827495-A1 SUBSTITUTED-PENT-4-YNOIC ACIDS SMITHKLINE BEECHAM CORPORATION (US) 1998-03-11 EP disclosed
CN-1175211-A 4, 4 -(disubstituted) cyclohexan-one monomers and related compounds SMITHKLINE BEECHAM CORP (US) 1998-03-04 CN disclosed
EP-0799183-A1 3,3-(DISUBSTITUTED)CYCLOHEXAN-1-ONE MONOMERS AND RELATED COMPOUNDS SMITHKLINE BEECHAM CORPORATION (US) 1997-10-08 EP disclosed
WO-1997003945-A1 SUBSTITUTED-PENT-4-YNOIC ACIDS SMITHKLINE BEECHAM CORPORATION (US) 1997-02-06 WO disclosed
WO-1996038150-A1 4.4-(DISUBSTITUTED)CYCLOHEXAN-1-OLS-MONOMERS AND RELATED COMPOUNDS SMITHKLINE BEECHAM CORPORATION (US) 1996-12-05 WO disclosed
WO-1996020158-A1 3,3-(DISUBSTITUTED)CYCLOHEXAN-1-ONE MONOMERS AND RELATED COMPOUNDS SMITHKLINE BEECHAM CORPORATION (US) 1996-07-04 WO disclosed
WO-1996019988-A1 4,4-(DISUBSTITUTED)CYCLOHEXAN-1-OLS MONOMERS AND RELATED COMPOUNDS SMITHKLINE BEECHAM CORPORATION (US) 1996-07-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130172352-A1 5-MEMBERED HETEROCYCLE-BASED P38 KINASE INHIBITORS MAPK1, MAP3K1, MAP3K8 L3MBTL1 2317/4885CHRNA7 3951/4885RAB9A 1140/4885
US-20120264801-A1 5-MEMBERED HETEROCYCLE-BASED P38 KINASE INHIBITORS MAPK1, MAP3K1, MAP3K8 L3MBTL1 2317/4885CHRNA7 3951/4885RAB9A 1140/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.